[1] L?we B, Spitzer RL, Williams JB, et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment[J]. Gen Hosp Psychiat, 2008, 30(3): 191-199. DOI: 10.1016/j.genhosppsych.2008.01.001.

[2] 何燕玲，馬弘，張嵐，等. 綜合醫(yī)院就診者中抑郁焦慮障礙的患病率調(diào)查[J]. 中華內(nèi)科雜志，2009, 48(9): 748-751. DOI: 10.3760/cma.j.issn.0578-1426.2009.09.010.

[3] Phillips MR, Zhang J, Shi Q, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey[J]. Lancet, 2009, 373(9680): 2041-2053. DOI: 10.1016/S0140-6736(09)60660-7.

[4] 姜榮環(huán)，黨衛(wèi)民，馬弘，等. 非精神科醫(yī)生對抑郁障礙的識別和相關(guān)因素[J]. 中華內(nèi)科雜志，2010, 49(6): 477-479. DOI: 10.3760/cma.j.issn.0578-1426.2010.06.007.

[5] 吳文源，魏鏡，陶明. 綜合醫(yī)院焦慮抑郁診斷和治療的專家共識[J]. 中華醫(yī)學雜志，2012, 92(31): 2174-2181. DOI: 10.3760/cma.j.issn.0376-2491.2012.31.008.

[6] Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies[J]. Int J Stroke, 2014, 9(8): 1017-1025. DOI: 10.1111/ijs.12357.

[7] Burton CA, Murray J, Holmes J, et al. Frequency of anxiety after stroke: a systematic review and meta-analysis of observational studies[J]. Int J Stroke, 2013, 8(7): 545-559. DOI: 10.1111/j.1747-4949.2012.00906.x.

[8] 中華醫(yī)學會神經(jīng)病學分會神經(jīng)心理學與行為神經(jīng)病學組，中華醫(yī)學會神經(jīng)病學分會帕金森病與運動障礙學組. 帕金森病抑郁、焦慮及精神病性障礙的診斷標準及治療指南[J]. 中華神經(jīng)科雜志，2013, 46(1) : 56-60. DOI: 10.3760/cma.j.issn.1006-7876.2013.01.015.

[9] Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis[J]. Epilepsia, 2007, 48(12): 2336-2344. DOI: 10.1111/j.1528-1167.2007.01222.x.

[10] Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer′s disease: an analysis of population-based data[J]. Lancet Neurol, 2014, 13(8): 788-794. DOI: 10.1016/S1474-4422(14)70136-X.

[11] 中國康復學會心血管病專業(yè)委員會. 在心血管科就診患者的心理處方中國專家共識[J]. 中華心血管病雜志，2014, 42(1): 6-13. DOI: 10.3760/cma.j.issn.0253-3758.2014.01.003.

[12] De Jong MJ, Chung ML, Roser LP, et al. A five-country comparison of anxiety early after acute myocardial infarction[J]. Eur J Cardiovasc Nur, 2004, 3(2): 129-134. DOI: 10.1016/j.ejcnurse.2004.01.004.

[13] FilipoVic BF, Randjelovic T, Ille T, et al. Anxiety, personality traits and quality of life in functional dyspepsia-suffering patients[J]. Eur J Intern Med, 2013, 24(1): 83-86.DOI: 10.1016/j.ejim.2012.06.017.

[14] Lin EH, Von Korff M, Alonso J, et al. Mental disorders among persons with diabetes-results from the World Mental Health Surveys[J]. J Psychosom Res, 2008, 65(6): 571-580. DOI: 10.1016/j.jpsychores.2008.06.007.

[15] Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies[J]. Lancet Oncol, 2011, 12(2): 160-174. DOI: 10.1016/S1470-2045(11)70002-X.

[16] Yang YL, Liu L, Wang Y, et al. The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2013, 13: 393. DOI: 10.1186/1471-2407-13-393.

[17] Andersen BL, Rowland JH, Somerfield MR. Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation[J]. J Oncol Pract, 2015, 11(2): 133-134. DOI: 10.1200/JOP.2014.002311.

[18] Lichtman JH, Bigger JT, Blumenthal JA, et al. AHA science advisory. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee to the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care Outcomes Research. Endorsed by the American Psychiatric Association[J]. Prog Cardiovasc Nurs, 2009, 24(1): 19-26. DOI: 10.1111/j.1751-7117.2009.00028.x.

[19] Kroenke K, Spitzer RL, Williams JB. The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms[J]. Psychosom Med, 2002, 64(2): 258-266.

[20] 莊琦，毛家亮，李春波，等. 軀體化癥狀自評量表的初步編制及信度和效度研究[J]. 中華行為醫(yī)學與腦科學雜志，2010, 19(9): 847-849. DOI: 10.3760/cma.j.issn.1674-6554.2010.09.026.

[21] Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders[J]. World J Biol Psychia, 2013, 14(5): 334-385. DOI: 10.3109/15622975.2013.804195.

[22] Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of Patients With Major Depressive Disorder(Third Edition)[D]. American Psychiatric Association, 2010.

[23] Baldwin DS, Anderson LM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology[J]. J Psychopharmacol, 2014, 28(5): 403-439. DOI: 10.1177/0269881114525674.

[24] Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study[J]. Br J Psychiatry, 2006, 189: 264-272. DOI: 10.1192/bjp.bp.105.012799.

[25] Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial[J]. JAMA, 2009, 301(3): 295-303. DOI: 10.1001/jama.2008.977.

[26] Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline[J]. J Clin Psychiatry, 2005, 66(1): 94-99.

[27] Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder[J]. Psychiatry Clin Neurosci, 2006, 60(3): 347-351. DOI: 10.1111/j.1440-1819.2006.01512.x.

[28] Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study[J]. J Clin Psychiatry, 2006, 67(6): 874- 881.

[29] Mokhber N, Azarpazhooh MR, Khajehdaluee M, et al. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder[J]. Psychiatry Clin Neurosci, 2010, 64(2): 128-133. DOI: 10.1111/j.1440-1819.2009.02055.x.

[30] Allgulander C, Hartford J, Russell J, et al. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials[J]. Curr Med Res Opion, 2007, 23(6): 1245-1252. DOI: 10.1185/030079907X182202.

[31] Allgulander C, Nutt D, Detke M, et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder[J]. J Psychopharmacol, 2008, 22(4): 417-425. DOI: 10.1177/0269881108091588.

[32] Gelenberg A, Lydiard R, Rudolph R, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial[J]. JAMA, 2000, 283(23): 3082-3088.

[33] Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study[J]. J Clin Psychiatry, 2012, 73(7): 1002-1008. DOI: 10.4088/JCP.11m07493.

[34] Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study[J]. J Clin Psychiatry, 2014, 75(4): 362-368. DOI: 10.4088/JCP.13m08433.

[35] Mitte K, Noack P, Steil R, et al. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder[J]. J Clin Psychopharmacol, 2005, 25(2): 141-150.

[36] Seedat S, van Rheede van Oudtshoorn E, Muller JE, et al. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study[J]. Int Clin Psychopharmacol, 2003, 18(5): 279-284. DOI: 10.1097/01.yic.0000085240.99018.79.

[37] Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multicenter, double-blind, placebo-controlled study in outpatients[J]. Psychiatry Res, 2001, 103(1): 1-14.

[38] Pollack M, Mangano R, Entsuah R, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder[J]. Psychopharmacology (Berl), 2007, 194(2): 233-242. DOI: 10.1007/s00213-007-0821-0.

[39] Moylan S, Staples J, Ward SA, et al. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder[J]. J Clin Psychopharmacol, 2011, 31(5): 647-652. DOI: 10.1097/JCP.0b013e31822d0012.

[40] Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study[J]. Pharmacopsychiatry, 2004, 37(5): 206-210. DOI: 10.1055/s-2004-832593.

[41] Alamy S, Wei Z, Varia I, et al. Escitalopram in specific phobia: results of a placebo-controlled pilot trial[J]. J Psychopharmacol, 2008, 22(2): 157-161. DOI: 10.1177/0269881107080796.

[42] Hashash JG, Abdul-Baki H, Azar C, et al. Clinical trial: a randomized controlled cross-over study of flupenthixol ＋ melitracen in functional dyspepsia[J]. Aliment Pharmacol Ther, 2008, 27(11): 1148-1155. DOI: 10.1111/j.1365-2036.2008.03677.x.

[43] 史麗麗，趙曉暉，王瑛，等. 烏靈膠囊治療焦慮、抑郁狀態(tài)的隨機雙盲對照研究[J]. 中華神經(jīng)科雜志，2009, 42(11): 776-779. DOI: 10.3760/cma.j.issn.1006-7876.2009.11.018.

[44] Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis[J]. Lancet, 2009, 373(9665): 746-758. DOI: 10.1016/S0140-6736(09)60046-5.

[45] Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study[J]. Br J Psychiatry, 2009, 195(3): 211-217. DOI: 10.1192/bjp.bp.108.051110.

[46] Fournier JC, DeRubeis RJ, Hollon SD, et al.Antidepressant drug effects and depression severity: a patient-level meta-analysis[J]. JAMA, 2010, 303(1): 47-53. DOI: 10.1001/jama.2009.1943.

[47] Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care[J]. Cochrane Database Syst Rev, 2009, 8(3): CD007954. DOI: 10.1002/14651858.CD007954.

[48] Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability[J]. Depress Anxiety, 1998, 7 Suppl 1: 11-17.

[49] Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double blind, placebo-controlled study[J]. Pain, 2004, 110(3): 697-706. DOI: 10.1016/j.pain.2004.05.010.

[50] Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder[J]. J Psychopharmacol, 2008, 22(8): 843-848. DOI: 10.1177/0269881107083808.

[51] Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis[J]. J Psychiatry Neurosci, 2006, 31(2): 122-131.

[52] Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient level meta analysis[J]. JAMA, 2010, 303(1): 47-53. DOI: 10.1001/jama.2009.1943.

[53] Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine[J]. J Clin Psychopharmacol, 2005, 25(2): 132-140.

[54] Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with longterm treatment[J]. J Clin Psychiatry, 2000, 61(11): 863-867.

[55] Lawton A, Moghraby OS. Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline CG28)[J]. Arch Dis Child Educ Pract Ed, 2016, 101(4): 206-209. DOI: 10.1136/archdischild-2015-308680.

[56] Laimler M, Kramer-Reinstadler K, Rauchenzauner M, et al.Effect of mirtazapine treatment on body composition and metabolism[J]. J Clin Psychiatry, 2006, 67(3): 421-424.

[57] Nutt DJ.Tolerability and safety aspects of mirtazapine[J]. Hum Psychopharmacol, 2002, 17 Suppl 1: S37-41.DOI: 10.1002/hup.388.

[58] Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR[J]. J Clin Psychopharmacol, 2008, 28(3): 329-333. DOI: 10.1097/JCP.0b013e318172b48c.

[59] Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer′s disease: a meta analysis[J]. Can J Psychiatry, 2007, 52(4): 248-255.

[60] Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression[J]. J Clin Psychiatry, 2005, 66(6): 708-716.

[61] Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study[J]. Am J Psychiatry, 2000, 157(3): 351-359. DOI: 10.1176/appi.ajp.157.3.351.

[62] Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports[J]. Biol Psychiatry, 2007, 62(4): 345-354. DOI: 10.1016/j.biopsych.2006.09.023.

[63] Hovorka J, Herman E, Nemcova I. Treatment of interictal depression with citalopram in patients with epilepsy[J]. Epilepsy Behav, 2000, 1(6): 444-447.

[64] Peng WF, Wang X, Hong Z, et al. The anti-depression effect of Xylaria nigripes in patients with epilepsy: A multicenter randomized double-blind study[J]. Seizure, 2015, 29: 26-33. DOI: 10.1016/j.seizure.2015.03.014.

[65] Zissis NP, Harmoussi S, Vlaikidis N, et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache[J]. Cephalalgia, 2007, 27(4): 315-324. DOI: 10.1111/j.1468-2982.2007.01300.x.

[66] Lespérance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial[J]. JAMA, 2007, 297(4): 367-379. DOI: 10.1001/jama.297.4.367.

[67] Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction[J]. Arch Gen Psychiatry, 2005, 62(7): 792-798. DOI: 10.1001/archpsyc.62.7.792.

[68] Glassman AH, O′Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina[J]. JAMA, 2002, 288(6): 701-709.

[69] Lustman PJ, Freedland KE, Griffith LS, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial[J]. Diabetes Care, 2000, 23(5): 618-623.

[70] Hollon SD, DeRubeis RJ, Fawcett J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial[J]. JAMA Psychiatry, 2014, 71: 1157-1164.DOI: 10.1001/jamapsychiatry.2014.1054.

[71] Brakemeier EL, Merkl A, Wilbertz G, et al. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial[J]. Biol Psychiatry, 2014, 76: 194-202. DOI: 10.1016/j.biopsych.2013.11.030.

[72] Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis[J]. J Psychiatry Neurosci, 2005, 30(2): 83-90.

[73] Dunn AL, Trivedi MH, Kampert JB, et al. Exercise treatment for depression: efficacy and dose response[J]. Am J Prev Med, 2005, 28(1): 1-8. DOI: 10.1016/j.amepre.2004.09.003.

[74] Siev J, Chambless DL. Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disorders[J]. J Consult Clin Psychol, 2007, 75(4): 513-522. DOI: 10.1037/0022-006X.75.4.513.

[75] Gross M, Nakamura L, Pascual-Leone A, et al. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies[J]. Acta Psychiatr Scand, 2007, 116(3): 165-173. DOI: 10.1111/j.1600-0447.2007.01049.x.

[76] Schr?der A, Rehfeld E, Ornb?l E, et al. Cognitive-behavioural group treatment for a range of functional somatic syndromes: randomised trial[J]. Br J Psychiatry, 2012, 200(6): 499-507. DOI: 10.1192/bjp.bp.111.098681.

[77] Heijmans M, Olde Hartman TC, van Weel-Baumgarten E, et al. Experts′ opinions on the management of medically unexplained symptoms in primary care. A qualitative analysis of narrative reviews and scientific editorials[J]. Fam Pract, 2011, 28(4): 444-455. DOI: 10.1093/fampra/cmr004.

相關(guān)知識

抑郁癥暴瘦怎么治療 焦慮癥暴瘦會恢復嗎
米國琳教授：準確識別心身疾病患者，制定個體化綜合治療方案
怎么防治產(chǎn)前抑郁焦慮障礙
班輝：產(chǎn)科心理健康：孕期焦慮與產(chǎn)后抑郁的科學應對
關(guān)于強化我國孕婦產(chǎn)后抑郁癥防治的提案
老年人抑郁癥有哪些癥狀
治療妊娠期的焦慮、抑郁情緒
孕產(chǎn)婦心理健康管理專家共識（2019年）
惡心、腹痛、暴瘦 可能是隱匿性抑郁在搗鬼
【專家共識】妊娠期及產(chǎn)褥期靜脈血栓栓塞癥預防和診治專家共識

網(wǎng)址: 綜合醫(yī)院焦慮、抑郁與軀體化癥狀診斷治療的專家共識 http://www.u1s5d6.cn/newsview44863.html